News Rob Bent News Rob Bent

7 Hills Pharma Receives $4.7MM Gra​nt to Advance First-in-class Cell/Gene Therapy Technology into the Clinic

7 Hills Pharma has been awarded a $4.7 million CPRIT grant to advance 7HP935, a first-in-class small molecule gene therapy that enhances hematopoietic stem cell transplantation (HSCT). This therapy aims to improve stem cell engraftment and reduce infection risks, offering a better treatment option for cancer and genetic disorder patients, especially those from ethnic minorities with limited stem cell donor matches.

Read More
News Rob Bent News Rob Bent

7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding

7 Hills Pharma has received a $13.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to advance 7HP349 (Alintegimod) into a Phase 1b/2a trial targeting PD-1-resistant solid tumors. This funding supports the development of a novel immunotherapy to overcome immune checkpoint inhibitor resistance, offering hope for checkpoint blockade-resistant patients.

Read More